2020-09

Trade agreements and the risks for the nursing workforce, nursing practice and public health: A scoping review

Kidgell, D

<http://hdl.handle.net/10026.1/16020>

10.1016/j.ijnurstu.2020.103676

International Journal of Nursing Studies

Elsevier BV

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

Trade agreements and the risks for the nursing workforce, nursing practice and public health: A scoping review

Dianna Kidgell¹ Danny Hills^{1, 2} Debra Griffiths¹ Ruth Endacott^{1, 3}

1. School of Nursing and Midwifery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Wellington Road, Clayton, Victoria 3800, Australia
2. School of Nursing and Healthcare Professions, Federation University Australia, P.O. Box 663, Ballarat, Victoria 3353, Australia
3. School of Nursing and Midwifery, University of Plymouth, Drake Circus, Plymouth PL48AA, United Kingdom

This is an accepted manuscript of an article published by Elsevier in *International Journal of Nursing*

Studies in May 2020 available at: <https://doi.org/10.1016/j.ijnurstu.2020.103676>

Abstract

Background

Trade agreements in the 21st century have evolved to include provisions that affect domestic public policy and public health in signatory countries. There are growing calls for health professionals and public health advocates to pursue an active advisory role in trade negotiations in order to anticipate and prevent negative outcomes for health services and public health.

Aim

This scoping review explored current literature to identify existing knowledge of the implications of trade agreements for the nursing workforce, nursing practice and public health using as an example the 2018 'Comprehensive and Progressive Agreement for Trans-Pacific Partnership'.

Design

Scoping review

Data Sources

Emerald Insight, Informit, Ovid MEDLINE, PubMed, ProQuest, Scopus, and a number of specialist Economics, International Trade and Business, and International Relations databases. Grey literature included national and international policy documents.

Review Method

Literature was selected according to extraction field criteria, supplemented by hand searching of relevant grey literature and snowballing references from the selected literature reference lists.

Analysis was undertaken to identify key themes emerging from the literature.

Review results

Six key themes relevant to nursing workforce, nursing practice or public health were 1. Lack of consultation with public health and health professionals in trade negotiations; 2. Implications of strengthened intellectual property provisions for equitable access to medicines (including biologics) and medical devices; 3. Threats to government capacity to regulate domestic policy for public health and health services through 'Investor State Dispute Settlement' provisions 4. Threats to government capacity to regulate domestic policy for public health and health services through 'Regulatory Coherence' 5. Potential limited benefits to communities and increased health inequities 6. Potential implications of increased temporary migration. Gaps were identified in the literature for implications for nursing practice and the nursing workforce from regulatory and labour provisions of trade agreements.

Conclusions

The analysis of the literature reviewed is of international importance for the nursing workforce, nursing practice and public health. Policymakers must anticipate and respond to how the inclusion of labour or regulatory provisions in trade agreements will affect nursing practice and the nursing workforce, and how this may subsequently impact on the health of communities globally.

Keywords

Nursing, Nursing workforce, Public Health, Scoping review, Trade in services, Trade agreement, Health services.

What is already known about this topic?

- There is limited evidence in the international literature on the impact of trade in goods and services agreements on the nursing workforce, nursing practice and public health.
- Some prospective analyses and commentaries have, nonetheless, considered and described potential implications of trade in goods and services agreements for public health.
- There is evidence that concerns raised by health advocates have resulted in the suspension of some controversial provisions of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership, although they have not been cancelled and may be reintroduced. Many of the suspended provision have now been introduced into the recent United States, Mexico, Canada Agreement (2018) while others such as 'Regulatory Coherence' have been expanded and strengthened.

What this paper adds?

- Provisions of trade in goods and services agreements have the capacity to adversely impact on the nursing workforce, nursing practice and public health.
- Gaps in the peer reviewed literature were identified for risks to the nursing workforce, nursing practice and public health from regulatory and labour provisions in the agreements.
- Further research into the potential benefits and challenges of each of these provisions in trade in goods and services agreements to the nursing workforce, nursing practice and public health is urgently required.
- Increased intrusions of trade agreement provisions into domestic public policy have risks for health services and public health. Health professionals, including nurses, and public health advocates must be afforded the same access to trade negotiators as traditional advisors in trade, finance and business law and that their subsequent advice is factored into trade agreements.

Trade agreements and the risks for the nursing workforce, nursing practice and public health: A scoping review

1. Introduction

The past two decades have seen a rapid increase in the number of trade agreements negotiated outside the World Trade Organization (WTO). Trade agreements in the 21st century have evolved to include provisions that affect domestic public policy and public health in signatory countries. Protections for health, which were established through the WTO, are being marginalised and new provisions place far greater constraint on domestic policy making (Gleeson & Labonté, 2020; Gleeson, Lexchin, Labonté, Townsend, Gagnon, Kohler, Forman & Shadlen, 2019). Issues such as intellectual property (patent) protections also continue to present a challenge to equitable global access to medicines (including biologics) and medical devices as pharmaceutical companies pursue new ways to extend product protection. Over the same period, there has been a growth in the power of markets to influence negotiation of these agreements. Trade agreements represent a point of potential conflict between public policy goals, the provisions of essential services and the profit motive of markets and trade.

These changes in trade agreements are occurring in the global context of increased demand for health services and the health workforce. At the same time, there is increased focus on the importance of the nursing workforce in the delivery of those services and in the achievement of the United Nations Sustainability Development Goals by 2030. For the nursing profession, these agreements have potential implications for nursing practice, the nursing workforce and workforce planning for sustainable and equitable health service delivery.

1.1 Brief History

107 The General Agreement on Tariffs and Trade, established in 1947, had both an economic and
108 political purpose. Following the devastation of two world wars and the great depression in the early
109 twentieth century, it was believed that increasing the wealth of countries and linking them through
110 trade would promote peace and prosperity. The agreement led to a massive expansion of world
111 trade which raised millions of people out of poverty (Johnston, 2019; Labonté, 2019; Schram,
112 Townsend, Youde, & Friel, 2019). In 1995, the General Agreement on Tariffs and Trade became the
113 WTO which now includes 164 member countries. The WTO oversees a number of international trade
114 agreements, including the General Agreement on Trade in Services, the Agreement on Trade Related
115 Intellectual Property Rights, and the Agreement on Trade Related Investment Measures.

116 The negotiations of agreements through the WTO were painfully slow and complex, requiring
117 consensus across a large number of countries and economies at different stages of development.
118 Countries struggled to agree on trade rules for such things as patent and data exclusivity protections
119 for medicines and medical devices. Many countries have now turned away from the multilateral
120 process toward bilateral or regional trade agreements and there has been a rapid increase in the
121 number of these agreements in the past two decades (Johnston, 2019; McNeill, Birkbeck, Fukuda-
122 Parr, Grover, Schrecker & Stuckler, 2017; Labonté et al. 2019, Bureau et al. 2019).

123 Trade agreements form a type of economic legal framework of rules and principles governing global
124 trade. Some commentators believe that the forces influencing the development of those rules
125 globally are increasingly dominated by private economic powers and very powerful countries
126 (Schram et al. 2019). At the same time, there has been a strong growth in neoliberalism, which
127 favours deregulation, reducing government spending, cutting taxes, competition and free markets.
128 The International Monetary Fund has noted that this strong global trend to neoliberalism has led to
129 increasing inequality rather than growth (Ostry, Loungani, & Furceri, 2016).

130 Traditionally, the policy areas of trade and health have operated separately (Gleeson & Labonté,
131 2020). However, these changes to trade agreements, coupled with increased cross-border flows in

goods, services, people and capital, affect public health and health services through a number of mechanisms (Smith, Blouin, & Drager, 2015). These mechanisms include the increased advertising and sale of unhealthy products, such as high sugar content foods and beverages, increased costs of medicines to health systems and consumers, ownership and capital investment by large international organizations in health infrastructure, and through impacts on key determinants of health such as employment, pollution and the environment (Smith, Blouin, & Drager, 2015; Gleeson & Labonté, 2020; Labonté et al. 2019; Schram et al. 2019).

The Comprehensive and Progressive Agreement for Trans-Pacific Partnership is one of the regional trade agreements negotiated outside of the WTO. The signatory countries are Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, Peru, New Zealand, Singapore and Vietnam.

There is a broad range of economic development across these countries from advanced, high-income economies such as Japan, to developing, lower middle-income economies such as Vietnam.

Based on the Trans-Pacific Partnership (2016), which faltered after the withdrawal of the United States in 2017, the Comprehensive and Progressive Agreement for Trans-Pacific Partnership is fundamentally the same agreement with suspension of some of the more contentious provisions. These suspensions remain in place unless the signatory countries unanimously agree that they are reintroduced. The suspended provisions of relevance to this discussion relate primarily to provisions that would have strengthened patent and data exclusivity protections for pharmaceuticals (Box1). These articles and Annexe 26A would have added additional periods of protection for patent and data exclusivity for pharmaceuticals which would have delayed the introduction of generic products to the market and significantly increased the cost to health systems and consumers (Pusceddu, 2018).

Box 1. Relevant suspended provisions

Article 18.37	Requirement for patents to be made available for either new uses of known products, new methods of using a known product or new processes of using a known product and for inventions derived from plants.
18.46	Requirement for governments to adjust, upon request, a patent's term of protection to compensate the patent owner if there are unreasonable delays in a patent office's issuance of patents.
18.48	Requirement to adjust a pharmaceutical patent's term of protection to compensate the patent owner for unreasonable curtailment of the effective term of a patent as a result of the marketing approval process for a pharmaceutical product.
18.50	Requirement for five years protection for data and test data submitted to a regulatory authority for the purpose of obtaining regulatory approval to market a pharmaceutical product.
18.51	Requirement for five years of protection for test or other data submitted to a regulatory authority for the purposes of obtaining regulatory approval to market a biologic pharmaceutical product.
Annexe 26A	'Transparency and Procedural Fairness for Pharmaceutical Products and Medical Devices' relating to the listing and pricing of pharmaceutical products and medical devices which would have increased and enforced the influence of pharmaceutical companies in the decisions of national health care authorities.

157

158

159 Public health advocates and health professionals have warned that these provisions may be

160 reinstated in the current agreement or introduced into other trade agreements (Labonté et al. 2019;

161 Labonté, Schram & Ruckert, 2017; Tham & Ewing, 2016). Indeed, the recently signed Canada, Mexico

162 and United States Trade Agreement (2018) includes expansions of intellectual property rights and

new regulatory reforms, which introduce regulatory constraints that intrude into domestic public policy (Labonté et al. 2019).

Supporters of these trade agreements claim that they will expand and grow current markets, and create new markets, while supporting the establishment of best practice regulation across signatory countries. Proponents also claim that they have the capacity to improve labour standards and working conditions across the region through the incorporation of the International Labour Organization (1998) 'Declaration on Fundamental Principles and Rights at Work' (Government of the Commonwealth of Australia, Department of Foreign Affairs and Trade, 2018b; Foreign Affairs Defence and Trade References Committee, 2018; Joint Standing Committee on Treaties, 2018).

Researchers and scholars of public health, health systems, health policy and international law are concerned about the rapid growth in the number of trade agreements and the growing dominance of influence from markets in negotiations. These experts warn that provisions in these agreements have the potential to adversely affect access to medicines (including biologics) and medical devices, and that they will erode the capacity of governments to use regulation to address issues of public health such as highly refined foods or high sugar content beverages and foods (Crosbie, Sosa & Glantz, 2018; Crosbie & Thomson, 2018; Crosbie, Thomson, Freeman & Bialous, 2018; Gleeson & Friel, 2013; Gleeson, Lexchin, Lopert, & Kilic, 2018; Gleeson, Moir, & Lopert, 2015; Jarman, 2017; Gleeson, Lexchin, Labonté, Townsend, Gagnon, Kohler, Forman & Shadlen, 2019; Labonté et al. 2019; Labonté, Schram, & Ruckert, 2016; Schram & Labonté, 2017; Schram et al. 2019; Thow, Snowdon, Labonté, Gleeson, Stuckler, Hattersley & Friel, 2015; Thow, Jones, Hawkes, Ali & Labonté, 2017; Tienhaara, 2011). Other concerns have been raised by political scientists and researchers in global economic governance who consider that the broad scope of these agreements make them influential in shaping policy decisions that influence other determinants of health such as equity of

access to health services, employment, pollution and the environment (Jarman, 2017; McNeill et al., 2017).

The majority of research to date in this rapidly evolving area of international trade has been through prospective analyses undertaken by public health and international law scholars. There is a gap in research of the potential implications particularly for the health workforce and public policy. Given the essential nature of health services and the health workforce, urgent further research of these issues is warranted. As health advocates, nurses have an important role in ensuring the sustainability, accessibility and equity of health services. Health system sustainability is also dependent on the health professionals that deliver health care to the community. The implications for the nursing workforce, the largest group of healthcare providers, must also be considered in order to anticipate and mitigate unintended consequences that may adversely affect health systems and the health outcomes of populations.

2. Method

2.1 Aim

The aim of this review is to explore current literature and identify existing knowledge concerning the implications of trade agreements relevant for the nursing workforce, nursing practice and public health. The 2018 Comprehensive and Progressive Agreement for Trans-Pacific Partnership (2018) will be used as an exemplar. A scoping review protocol was developed based on *The Joanna Briggs Institute Reviewers' Manual 2015: Methodology for JBI Scoping Reviews* (Peters, Godfrey, McInerney, Soares, Khalil, & Parker, 2015).

2.2 Search Criteria

The inclusion criteria for this review were English language, full-text, peer-reviewed journal articles, as well as grey literature including national and international policy documents published between 2016 and 2019.

2.3 Search strategy and outcomes

Six databases were searched – Emerald Insight, Informit, Ovid-MEDLINE, ProQuest, PubMed, Scopus. Search terms included ‘trade in services agreements’, ‘free trade agreements’, ‘Trans-Pacific Partnership’ ‘TPP-11’ ‘Trans-Pacific agreement’, ‘harmonisation of regulation’, ‘regulatory coherence’, Health*, Medic*, Nurs*, ‘nurse migration’, workers, ‘workforce planning’ and variations of spelling in relation to these terms.

As shown in Figure 1, 872 abstracts were sourced from the databases, and 49 additional items were sourced from grey literature using Google Scholar, hand searching and snowballing from reference lists and peer referral. After the removal of duplicates, screening of titles and review of abstracts, 139 titles remained. Following full text review, a further 14 were discarded as being not relevant to context, three were discarded as not related to concept and 10 were discarded as not related to population. A total of 112 journal articles and items of grey literature were subsequently included in the review (Table 1 – Supplementary data). Each document was reviewed thoroughly, using the six-step thematic approach described by Braun & Clark (2006), in order to identify key themes relating to risks for the nursing workforce, nursing practice and public health (Table 2).

Figure 1. Literature search PRISMA flow diagram

Table 2. Braun and Clarke’s (2006) six-phase framework for ‘reflexive thematic analysis’

Phase	Action
1.	Become familiar with the data
2.	Generate Initial Codes
3.	Search for themes
4.	Review themes
5.	Define themes
6.	Write up

3 Results

Six key themes were identified relating to risks for the nursing workforce, nursing practice and public health.

3.1. Lack of consultation with health professionals and public health advocates in trade negotiations

Trade agreements reflect the interests of those directly involved in the system (Schram et al, 2019). Trade negotiations are usually the responsibility of trade and finance or foreign affairs ministries of governments. Government trade negotiators are drawn from the experts in the areas of trade, finance, foreign affairs and international law rather than public health and health services (Jarman,2017). Access to trade negotiators is usually dominated by trade and finance interests. For example, the United States appointed approximately 600 corporate lobbyists as official advisors during the negotiations for the Trans-Pacific Partnership (Alcorn, 2016; Schram et al. 2019).

Health advocates argue that the essential nature of health services, and the critical importance to the community, differentiates them from traditional areas involved in trade negotiations. Any intended

policy change that may affect the provision of health services must, therefore, be analysed by experts in health service delivery to avoid unintended negative consequences for health systems (Alcorn, 2016; Jarman, 2017; Joint Standing Committee on Treaties, 2018; Schram et al. 2019; Smith et al. 2009).

Currently, opportunities for health advocates to advise on trade agreements are limited and usually occur without access to the draft agreement until late in the negotiation stage or after the agreement has been drafted (Joint Standing Committee on Treaties, 2018). Because these agreements have significant potential to affect health system resources and policies, as well as the social determinants of health, there is an urgent need for consultation with health stakeholders including public health advocates and the health professions (Jarman, 2017). Some commentators consider that trade negotiations provide an important opportunity to advance the health agenda. They urge public health advocates and the health professions to engage with the process and work toward greater inclusion in these negotiations (Alcorn, 2016; Schram et al. 2019).

As trade agreements evolve the potential for intrusion into domestic public policy increases the risks for public health and health services. There is a compelling need for health professions and public health advocates to have greater access to trade negotiators. Similarly, governments need to consult with and take advice from health professions and public health experts when negotiating trade agreements in order to anticipate and avoid negative unintended consequences for communities.

3.2 Implications of strengthened intellectual property provisions for equitable access to medicines (including biologics) and medical devices.

Pharmaceutical companies invent new medicines (including biologics) and medical devices that may take many years and significant investment to develop, trial and produce for the market. The Agreement on Trade-Related Aspects of Intellectual Property Rights (World Trade Organization,

1995) provides protections, through patents, which grant periods of 20 years monopoly rights to the inventing company. A registered patent provides the owner of the invention with the exclusive right to exploit it commercially for the life of the patent. During this time, no other company can produce a generic product for the market. This enables the company to recoup development costs and profit from the invention, thereby encouraging further investment and research.

However, at the same time as the WTO introduced the Agreement on Trade-Related Aspects of Intellectual Property Rights, the world was dealing with the unprecedented health crisis of the Acquired Immune Deficiency Syndrome (AIDS), caused by the Human Immunodeficiency Virus (HIV) (t' Hoen, 2016). Death rates from this disease were devastating for developing countries where millions of citizens were infected. The Agreement on Trade Related Intellectual Property created barriers to affordable, rapid and equitable access to cost-effective HIV medicines in many developing countries. As a result, a global campaign was launched by public health advocates, non-government organisations and health professionals, which succeeded in enabling the production of quality, generic HIV pharmaceuticals and access for millions of people to these lifesaving medicines (t' Hoen, 2016).

The WTO eventually agreed on the inclusion of protections for public health in trade negotiations and a framework of rules were established. The Doha Declaration on TRIPS (Trade-Related Aspects of Intellectual Property Rights) and Public Health in 2001, and the WTO 2005 Ministerial Declaration introduced Article. 31bis to the original agreement, creating 'compulsory licence' granting exemption for developing countries to produce and export generic pharmaceuticals for their own population, and other developing countries in a declared health crisis (Abbott, 2006; Pusceddu, 2018, t' Hoen, 2016).

Data exclusivity is a second type of protection for pharmaceutical companies, which relates to the process of developing new medicines (including biologics) or medical devices through clinical trials undertaken to establish that product is safe and effective. Data exclusivity refers to the period during which another pharmaceutical manufacturer cannot rely on the data generated by the inventing pharmaceutical company to gain marketing approval for their own generic products. This means that the generic manufacturer must wait until the period of data exclusivity expires or undertake their own clinical trials before they can begin manufacturing the product. When intellectual property protections expire, these products can be produced and sold as generic brands by other companies, usually at a much-reduced cost to the consumer.

Over the past two decades, pharmaceutical companies have pursued additional protections for products beyond those of the Trade-Related Aspects of Intellectual Property Rights, through the bilateral and regional trade agreements negotiated outside the WTO. The Comprehensive and Progressive Agreement for Trans-Pacific Partnership, and succeeding bilateral and regional agreements including the Comprehensive Economic and Trade Agreement (CETA) between the EU and Canada, and the United States-Mexico-Canada Agreement (USMCA), have included extended intellectual property protections. As indicated above, many of the provisions that would have enabled greater periods of exclusive patent to pharmaceutical companies were suspended in the Comprehensive and Progressive Agreement for Trans-Pacific Partnership. However, those provisions are extended and enforceable in the other trade agreements. These “TRIPSPlus” protections include such things as increases in the length of patent periods and periods of data exclusivity (Gleeson et al, 2019).

There are also other areas of these agreements that enhance these protections. These include provisions such as:

- Protections for investments through investor state dispute settlement provisions

- Procedural requirements for pharmaceutical pricing and reimbursement programs
- Provisions with implications for regulation of pharmaceutical marketing
- Regulatory requirements for assessment of safety, efficacy, and quality
- Reduction/elimination of tariffs on medicines or their ingredients
- Rules applying to government procurement of pharmaceuticals
- Rules applying to state-owned enterprises and designated monopolies
- Procedural requirements for customs administration and trade facilitation
- Rules applying to regulatory practices, cooperation and coherence (Gleeson et al, 2019).

Public health advocates and health professionals have expressed serious concerns about the implications of strengthened intellectual property protections in trade agreements for equity of access and cost of medicines (including biologics) and medical devices. The issue is extremely important for low and middle-income economies that rely on low cost generic medicines for the treatment of conditions such as Malaria, Tuberculosis and HIV. Any changes that further strengthen patent protections for medicines (including biologics) and medical devices put at risk the WTO Doha Declaration by creating barriers to affordable and equitable access to pharmaceuticals for communities globally (Crosbie, Sosa & Glantz 2018; Crosbie & Thomson, 2018; Crosbie, Thomson, Freeman & Bialous, 2018; Gleeson & Friel, 2013; Gleeson, Lexchin, Lopert, & Kilic, 2018; Gleeson, Moir, & Lopert, 2015; Gleeson et al, 2019; Jarman, 2017; Labonté et al. 2019; Labonté, Schram, & Ruckert, 2016; Pusceddu, 2018; Schram & Labonté, 2017; McNeill et al, 2017; Schram et al. 2019; Thow, Snowden, Labonté, Gleeson, Stuckler, Hattersley & Friel, 2015; Thow, Jones, Hawkes, Ali & Labonté, 2017; Tienhaara, 2011).

From this literature review, it is clear that a conflict exists between the commercial perspective of pharmaceutical companies, the objectives of public health and public health services, and the basic human right to equitable access to medicines globally. Opinion also varies on what constitutes

appropriate remuneration for the investment and research involved in inventing new pharmaceuticals and the degree to which profits translate into further investment and research (Light & Lexchin, 2012). There can be no doubt that health professionals and public health advocates must remain vigilant in all trade negotiations to prevent the introduction of provisions that can effectively limit access to and raise the cost of medicines beyond the reach of the disadvantaged in our communities.

3.3 Threats to government capacity to regulate domestic public health policy from ‘Investor State Dispute Settlement’ provisions.

Governments control access to their country’s markets and investments through various tariffs or quantitative restrictions on goods, and through domestic regulation. In the case of regulation, governments must balance the maintenance of domestic regulatory autonomy and liberalising access to markets and investment (Voon, 2017). Fifty years ago, an international system of arbitral jurisprudence was created to protect the rights of foreign investors from government policies and regulations that discriminate de facto against foreign goods, services or investors, or fail to meet other standards required by international economic law, such as the ‘fair and equitable treatment’ of foreign investors (Lencucha, 2017; Sheargold & Mitchell, 2016).

Many countries have given investors rights to arbitration through this system of international tribunals. Called ‘Investor State Dispute Settlement’, the system has developed rapidly in the 21st century through a vast network of bilateral and multilateral trade agreements. The tribunals are arbitrated by three lawyers, usually drawn from international business law. This has led to criticism that the tribunals favour business interests and are not qualified to adjudicate on matters related to challenges to public laws and sovereignty of countries in determining domestic policy for areas such as public health and health services (Jarman, 2019; Labonté et al., 2019; Schram et al. 2019; Puig &

Strezhnev, 2017). The system of arbitral jurisprudence has also been described as inconsistent, particularly in relation to the sums of compensation being awarded. Compensation payments have increased steadily from the beginning of the century to huge sums amounting to many billions of dollars. In some cases, the compensation has been far in excess of the investment. For example, Unión Fenosa Gas filed a claim against Egypt, which resulted in compensation awarded at USD 2.013 billion plus interest. This sum equated to 12 percent of the country's combined health and education budget at that time (Bonnitcha & Brewin, 2019). Arbitration tribunals also operate outside the national laws of the countries involved and have been described as undemocratic (Scram et al. 2019; Puig & Strezhnev, 2017).

Health advocates have criticised Investor State Dispute Settlement provisions of trade agreements as providing a mechanism by which companies can impede government efforts to regulate in the national interest, particularly for health-related issues such as tobacco, high sugar content foods and beverages, and alcohol labelling. There is growing concern that Investor State Dispute Settlement is now increasingly encroaching on government autonomy and capacity to regulate both directly, through a growing number of challenges in international courts, and through a phenomenon called 'Regulatory Chill' (Tienhaara, 2011; Lencucha, 2017; Crosbie & Thomson, 2018; Labonté et al. 2019; Schram & Labonté, 2017; Schram et al. 2019.).

'Regulatory Chill' refers to the unwillingness of government to introduce regulation for fear of a possible challenge under Investor State Dispute Settlement provisions. It has been argued that large companies have the financial capacity to use the system as a deterrent to governments and to dissuade regulation, even if they do not expect to 'win the case' (Lencucha, 2017). This creates a hostile regulatory environment in which governments hesitate to enact regulations in the public interest (Crosbie, Sosa & Glantz 2018; Crosbie & Thomson, 2018; Crosbie, Thomson, Freeman & Bialous, 2018; Friel, Gleeson, Thow, Labonté, Stuckler, Kay & Snowden, 2013, Gleeson & Friel, 2013;

Gleeson, Lexchin, Lopert, & Kilic, 2018; Gleeson, Moir, & Lopert, 2015; Labonté, Schram, & Ruckert, 2016; Labonté et al. 2019; Schram & Labonté, 2017; Schram et al. 2019; Thow, Snowden, Labonté, Gleeson, Stuckler, Hattersley & Friel, 2015; Thow, Jones, Hawkes, Ali & Labonté, 2017; Tienhaara, 2011).

Investor State Dispute Settlement provisions of trade agreements provide investors with protections against exclusionary government practices or policies. They also have the potential to influence the ways in which governments regulate domestically for the public good. The most obvious areas of concern for public health advocates, including nurses, are such things as the capacity to regulate sugar content in food and beverages or tobacco and alcohol, the environment, and pollution. There are also many other potential areas of concern such as ownership of private acute, aged care and retirement health facilities, and education and training providers responsible for educating future health professionals.

3.4 Threats to government capacity to regulate domestic public health policy from ‘Regulatory Coherence’ provisions of trade agreements.

Regulatory coherence is a concept that was included for the first time in the Comprehensive and Progressive Agreement for Trans-Pacific Partnership, as a way of introducing ‘best practice’ regulations across signatory countries and reducing protectionist domestic regulation. In this agreement the provisions are not legally binding. Since then, however, the provisions of ‘Regulatory Coherence’ in the recently signed United States, Mexico, Canada Agreement (2018) are expanded and are also legally binding (Labonté et al. 2019; Trans-Pacific Partnership Agreement, 2018).

Regulatory coherence is another pathway through which markets can influence public policy and dissuade government regulation that impedes trade. When combined with the actual and deterrent

461 impact of Investor State Dispute Settlement provisions, there is a significant risk for the public sector
462 and public policy from market forces and powerful countries in such areas as public health, health
463 services, the environment and pollution (Labonté et al. 2019).

464
465 Regulation intersects with many aspects of the educational, professional and practice environment
466 of nurses. The scope of these provisions has implications in areas including the regulation of
467 investment in health and aged care services and the educational organisations that prepare health
468 professionals for practice. Regulatory coherence is intended to reduce obstructive regulatory
469 requirements that act as a barrier to trade. Regulation of the health care sector, including health
470 service delivery, education of health professionals, and the regulation of nursing and other health
471 professions is complex and has a primary purpose of protecting the public. The balance of
472 opportunities and risks in the introduction of provisions that have the potential to affect health
473 service regulation, is a key policy issue. Research into the benefits and potential unintended
474 consequences of the introduction of regulatory coherence must be given high priority.

476 **3.5 Potential limited benefits to communities and increased health inequities.**

477
478 The labour provisions of the Comprehensive and Progressive Agreement for Trans Pacific
479 Partnership have been described as “the most significant labour clause in a trade agreement
480 concluded to date” (Tham & Ewing, 2016, p.2). The provisions address labour rights included in the
481 ‘Declaration on Fundamental Principles and Rights at Work’ (International Labour Organization,
482 1998). They require signatory countries to have laws at the Federal level of government that
483 enshrine the rights stated in the Declaration. Included are such important human rights as:

- 484 *(a) freedom of association and the effective recognition of the right to collective bargaining;*
485 *(b) the elimination of all forms of forced or compulsory labour; (c) the effective abolition of*
486 *child labour and, for the purposes of this Agreement, a prohibition on the worst forms of*

child labour; and (d) the elimination of discrimination in respect of employment and occupation (International Labour Organization, 1998).

However, the obligations set out in Article 19.3 (Labour Rights) of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership have been criticised for only including the International Labour Organization Declaration and not the more enforceable ‘Fundamental Conventions’ (International Labour Organization, 2002). These obligations are only enforceable where they affect trade or investment between signatory countries. Some commentators have questioned the level of adoption achievable of the labour clauses (Tham & Ewing, 2016). Others question whether access to these labour rights would be available to workers in insecure and unprotected employment, such as casual employment or working outside trade sectors directly included in the agreement. Workers in these positions could experience reduced benefits in actual health outcomes, and a decline in access to health services and health equity, relative to any material gain for the country’s economy that they may experience (McNamara and Labonté, 2017; Blouin, Chopra, & van der Hoeven, R, 2009). Although the conditions under which people live, work and die are a less direct and harder to assess social determinant of health than the impact of intellectual property protections and its consequences for equity of access to medicines, they are equally important (McNeill et al. 2017).

In summary, the Comprehensive and Progressive Agreement for Trans-Pacific Partnership includes the International Labour Organization (1998) ‘Declaration on Fundamental Principles and Rights at Work’ as part of its labour provisions. These provisions are not enforceable and sections of communities may see no benefit from the inclusions or may see a deterioration in their social determinants of health. Groups such as those in insecure or unprotected work, and those working outside industries directly included in the trade agreement fall within this category. The entitlement of all workers to fundamental rights, as outlined in the ‘International Labour Organization

Declaration’ (1998) and ‘Fundamental Conventions’ (2002), contribute to the social determinants of health and are of critical importance to ensuring health equity for communities.

3.6 Potential implications of increased temporary migration

Trade agreements include provisions for the temporary access of workers between countries. These provisions and the specific undertakings of each country form the requirements for workers, including nurses, to move between countries that are signatory to the agreement under temporary migrant status. Often governments include a requirement for employers to demonstrate their inability to fill the positions with domestic workers, called labour market testing or economic needs testing, before contracting workers outside the domestic workforce. In the Comprehensive and Progressive Agreement for Trans-Pacific Partnership, this requirement has been waived reciprocally for six of the signatory countries - Australia, Brunei Darussalam, Canada, Japan, Malaysia, Mexico and Vietnam.

In Australia, the waiver of the labour market testing requirement has caused significant concern. Many submissions to the parliamentary inquiries into the Comprehensive and Progressive Agreement for Trans-Pacific Partnership were about this issue. The Australian Nursing and Midwifery Federation expressed strong concerns for both the status and conditions of employment of temporary migrant nurses and other health workers, and the implications for the domestic nursing workforce. They asserted that, “acceptance of the need for temporary skilled migration is based on the view that appropriate policy and regulatory settings should discourage employers accessing offshore labour without first investing in training and undertaking genuine testing of the local labour market and must provide safeguards and protections for both local and overseas workers” (Australian Nursing and Midwifery Federation, 2018, p 6).

Australia, Canada and Japan, like other high income developed countries are facing increased demand for health services from a rapidly ageing population (Health Workforce Australia, 2014). In the recent past, Japan has managed increased demand for nurses through economic partnerships established with Indonesia (2008), the Philippines (2008) and Vietnam (2012) for nurses to work in the caregiving facilities in the aged care sector (Ford & Kawashima, 2016). These partnerships support the immigration of nurses for temporary contracts while making no change to permanent migration (Ford, & Kawashima, 2016). This has allowed the Japanese government to avoid labour challenges from a unionised workforce and negative community attitudes to immigration. A precedent has also been set for the use of trade agreements as a mechanism for management and regulation of labour flows leading to the normalisation of migrant labour as a tradable commodity (Ford, & Kawashima, 2016; Hoekman, & OeZden, 2010; Jarman, & Greer, 2010; Jurje, & Lavenex, 2018; Labonté et al. 2019).

The capacity to employ temporary migrant nurses offers healthcare providers increased flexibility and nursing capacity in anticipation of significant predicted shortages of nurses (Health Workforce Australia, 2014), and in recruiting to high demand specialities such as aged care and to geographically remote and rural health settings. Some commentators consider the use of trade in services agreements to facilitate worker migration as having potential for significant gains for both partner countries and individuals (Barker, 2010). However, in countries that have not included a labour market testing requirement, this will potentially bring temporary visa nurses into competition with domestic nurses for employment opportunities. The implications of a potential increase in competition for nursing employment have yet to be explored. The availability of nurses through temporary migration may lead to downward pressure on wages for nurses, and increases in casualization and insecure employment of the nursing workforce (Mashayekhi, Julsaint, & Tuerk, 2006).

The advantages of the temporary emigration of nurses, for source countries, include the benefit to the economy of remittances from expatriate workers, and the exchange of knowledge and technology on their return. For individual nurses, temporary migration provides an opportunity to earn wages at a higher level, for better working conditions and for professional development (Ramasamy, Krishnan, Bedford, & Bedford, 2008). The disadvantages, however, can include the depletion of adequate workers within the source country to meet its own population health needs, particularly in the public sector and remote locations.

High levels of nurse emigration can also prove a significant financial burden on the country to educate and prepare nurses for both domestic and overseas demand. Outcomes depend greatly on whether the country has sufficient training capacity to educate enough nurses to support its own health care system and community as well as an emigrating population of nurses (Labonté et al., 2015; Li, Nie & Li, 2014; Liua, Goryakin, Maeda, Bruckner, & Scheffler, 2016; Manning, Sidorenko, 2007). Unfortunately, government health and trade portfolios are usually managed separately and there may not be harmony in policy decisions that can achieve both the health policy goals and the economic trade goal (Labonté et al., 2015; Li, Nie & Li, 2014; Liua, Goryakin, Maeda, Bruckner, & Scheffler, 2016; Manning, Sidorenko, 2007). In countries such as the Philippines, for example, the number of nurses being produced is adequate for the health system, but nurses qualify with the expectation of migrating to countries like Australia, Canada, Japan, the United Kingdom and the United States, and are supported by government policy to do so. Government health workforce strategies focused on export can frustrate efforts to ensure an adequate workforce of nurses for the home country (Yeates & Pillinger, 2018).

For the destination country, reliance on temporary workers may be an economical and immediate solution to nurse shortages. However, failure to address the factors contributing to domestic nurse shortages, such as recruitment to the profession, available education places and retention of nurses

in the profession is likely to lead to further long-term exacerbation of domestic shortages (Health Workforce Australia, 2014; Australian Nursing and Midwifery Federation, 2018).

For individual nurses, migrating to work in another country's health system can also have negative outcomes (Kurniati, Chen & Efendi, 2017). These can include difficulty in gaining recognition and employment at the practice level attained in the home country, potential deskilling and loss of employment opportunities on return home (Ford & Kawashima, 2016; Kurniati, Chen, Efendi, & Ogawa, 2017). For example, Indonesian nurses recruited to work in Japan's aged care sector, under the Japan-Indonesia Economic Partnership (2008), struggled to reenter nursing practice in Indonesia at least at the level formerly achieved (Ford & Kawashima, 2016; Kurniati, Chen, Efendi, & Ogawa, 2017).

There are significant potential benefits and challenges from changes to the temporary migrant visa provisions of the trade agreements including the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (Foreign Affairs Defence and Trade References Committee, 2018; Joint Standing Committee on Treaties, 2018). However, little is known of how these changes may affect the nursing workforce and the healthcare systems dependent upon nurses to function effectively. Further research is urgently needed to address this gap in knowledge.

3. Discussion

The aim of this review was to explore current literature and identify existing knowledge of the implications of trade agreements relevant to the nursing workforce, nursing practice and public health, with a particular focus on the *Comprehensive and Progressive Agreement for Trans-Pacific Partnership* (2018). Six themes were identified as having relevance for the nursing workforce,

nursing practice and public health. Each of these falls within the scope of the definition of nursing, defined as encompassing:

... autonomous and collaborative care of individuals of all ages, families, groups and communities, sick or well and in all settings. Nursing includes the promotion of health, prevention of illness, and the care of ill, disabled and dying people. Advocacy, promotion of a safe environment, research, participation in shaping health policy and in patient and health systems management, and education are also key nursing roles (ICN, 2002).

The nursing profession can bring to trade negotiations the broad scope of expert knowledge and experience across all aspects of the health care environment, as well as an invaluable, multifaceted overview of a complex and interrelated system of service delivery, and environmental and social factors contributing to the health outcomes of the community. However, as has been discussed, opportunities for the health professions and public health advocates to contribute to trade agreements negotiations are currently limited (Schram et al.2019).

As trade and investment intrude further into the areas of public policy areas such as public health, health service delivery and the environment, advice from groups with expertise in these sectors will be essential to prevent unintended negative consequences and enhance positive outcomes. Nurses, other health professionals and public health advocates must make the case to governments for more direct access to government trade negotiations. Governments need to be fully aware of the potential unintended implications of trade provisions, how to include special protections for health and public policy, and how the terminology used in agreement texts can ensure those protections are enacted (Delany, Signal & Thomson, 2018).

4. Conclusion

The analysis of the literature reviewed is of international importance. The essential nature of the contribution of nursing to the effective provision of accessible and equitable health care adds a degree of urgency for research evidence which will support policy makers in anticipating and responding to labour and regulatory provisions in trade agreements that may impact on the nursing workforce, nursing practice and public health. A united approach by health professional and public health associations is also likely required to ensure the necessary protection for health systems and the health of communities.

Conflicts of interest

The authors declare no conflicts of interest.

References

- Abbott, F. (2006). The WTO Decision: World Pharmaceutical Trade and The Protection of Public Health. *The American Journal of International Law*, 99(2), 317.
doi: 10.2307/1562501
- Agitha, T. G. (2013). Impact of IP on public health: The developed country scenario. *Journal of Intellectual Property Rights*. 18(4), 382-389.
- Agitha, T. G., (2013). TRIPS agreement and public health: The post Doha crises. *Journal of Intellectual Property Rights*, 18(3), 287-293.
- Alcorn, T. (2016). TPP: Trade-offs for health behind closed doors. *The Lancet*, 387(10022), 929-930.
doi: 10.1016/S0140-6736(16)00632-2.
- Arksey, H., & O'Malley, L. (2005). Scoping studies: Towards a methodological framework. *International Journal of Social Research Methodology*, 8, 19-32.
doi: 10.1080/1364557032000119616.
- Australian Nursing and Midwifery Federation. (2018). Submission to the senate legal and constitutional affairs committee – The effectiveness of the current temporary skilled visa system in targeting genuine skills shortages. Retrieved from http://anmf.org.au/documents/submissions/ANMF_Submission_Skilled_Migration_Dec18.pdf
- Barker, F. (2010). Maximizing the migration policy buck: Uniting temporary labor, development and foreign policy goals in New Zealand. *Policy and Society*, 29(4), 321-331.
doi: 10.1016/j.polsoc.2010.09.008
- Barlow, P., Labonté, R., McKee, M., & Stuckler, D. (2018). Trade challenges at the World trade Organization to national noncommunicable disease prevention policies: A thematic document analysis of trade and health policy space. *PLoS Med*, 15(6) e1002590.

679 Barlow, P., McKee, M., Basu, S., & Stuckler, D. (2017). The health impact of trade and investment
680 agreements: a quantitative systematic review and network co-citation analysis. *Global Health*,
681 13(1), 13.

682 Blouin, C. (2017). Trade policy and health: Adding retrospective studies to the research agenda.
683 comment on “The Trans-Pacific Partnership: Is It Everything We Feared for Health?”.
684 *International Journal of Health Policy and Management*. 6(4), 243-244.

685 Blouin, C., Gobrecht, J., Lethbridge, J., Singh, D., Smith, R., & Warner, D. (2006). Trade in health
686 services under the four modes of supply: Review of current trends and policy issues (pp. 141-
687 167). In, C. Blouin, N. Drager & R. Smith (Eds.), *International trade in health services and the*
688 *GATS: Current issues and debates*. Washington, DC: The International Bank for Reconstruction
689 and Development/The World Bank. Retrieved from [http://www.nsi-ins.ca/wp-](http://www.nsi-ins.ca/wp-content/uploads/2012/10/2006-International-Trade-in-Health-Services-and-the-GATS-Current-Issues-and-Debates.pdf)
690 [content/uploads/2012/10/2006-International-Trade-in-Health-Services-and-the-GATS-Current-](http://www.nsi-ins.ca/wp-content/uploads/2012/10/2006-International-Trade-in-Health-Services-and-the-GATS-Current-Issues-and-Debates.pdf)
691 [Issues-and-Debates.pdf](http://www.nsi-ins.ca/wp-content/uploads/2012/10/2006-International-Trade-in-Health-Services-and-the-GATS-Current-Issues-and-Debates.pdf)

692 Blouin, C., Chopra, M., & van der Hoeven, R. (2009). Trade and social determinants of health. *The*
693 *Lancet.*, 373(9662), 502–507. doi.org/10.1016/S0140-6736(08)61777-8

694 Bonnitcho, J. & Brewin, S. (2019). Compensation Under Investment Treaties. Canada. The
695 International Institute for Sustainable Development. Retrieved from
696 [https://www.iisd.org/sites/default/files/publications/compensation-treaties-best-practices-](https://www.iisd.org/sites/default/files/publications/compensation-treaties-best-practices-en.pdf)
697 [en.pdf](https://www.iisd.org/sites/default/files/publications/compensation-treaties-best-practices-en.pdf)

698 Braun, V. & Clarke, V. (2006). Using thematic analysis in psychology. *Qualitative Research in*
699 *Psychology*, 3 (2). pp. 77-101. <http://dx.doi.org/10.1191/1478088706qp063oa>

700 Braun, V. & Clarke, V. (2019). Reflecting on reflexive thematic analysis, *Qualitative Research in Sport,*
701 *Exercise and Health*. *Qualitative Research in Sport, Exercise and Health*, 11(4), 589-597, DOI:
702 10.1080/2159676X.2019.1628806

703 Bureau, JC., Guimbard, H. & Jean, S. (2019). Competing liberalizations: tariffs and trade in the
704 twenty-first century. *Review of World Economics*, 155(4), 707 – 708.

<https://doi-org.ezproxy.lib.monash.edu.au/10.1007/s10290-019-00346-1>

Chandra, R. (2011). Mapping the Universe of services disciplines in Asian PTA's . An "NCCR Trade Working Paper". NCCR Trade Regulation. Swiss national centre of competence in research.

Retrieved from <https://www.semanticscholar.org/paper/Mapping-the-Universe-of-Services-Disciplines-in-Chanda/67ef089f1032c5db8052a1c7b4e42808076faa43>

Chandrasekharan, S., Amin, T., Kim, J., Furrer, E., Matterson, A. C., Schwalbe, N. & Nguyen, A. (2015).

Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers. *Vaccine* 33(46), 6366-6370.

Comprehensive and Progressive Agreement for Trans-Pacific Partnership (2018). Canberra:

Commonwealth of Australia. Retrieved from <https://dfat.gov.au/trade/agreements/in-force/cptpp/official-documents/Pages/official-documents.aspx>

Crosbie, E. & Thomson, G. (2018). Regulatory Chills: Tobacco Industry Legal Threats and the Politics of Tobacco Standardised Packaging in New Zealand. *New Zealand Medical Journal*. 131(1473),

25-41. Retrieved from <https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2018/vol-131-no-1473-13-april-2018/7540>

Crosbie, E., Sosa, P. & Glantz, S.A. (2018). Defending Strong Tobacco Packaging and Labelling Regulations in Uruguay: Transnational Tobacco Control Network Versus Philip Morris

International. *Tobacco Control*. 27(2), 185-194. Retrieved from

<https://tobaccocontrol.bmj.com/content/27/2/185>

Crosbie, E. Thomson, G. Freeman, B. & Bialous, S. (2018). Advancing Progressive Health Policy to

Reduce NCDs Amidst International Commercial Opposition: Tobacco Standardised Packaging in Australia. *Global Public Health* 13(12):1753-1766. doi: 10.1080/17441692.2018.1443485

Crosbie, E. & Glance, S. A. (2014). Tobacco industry argues domestic trademark laws and

international treaties preclude cigarette health warning labels, despite consistent legal advice that the argument is invalid. *Tobacco Control* 23(3).

731 Crosbie, E., Gonzalez, M. & Glantz, S.A. (2014). Health preemption behind closed doors; trade
732 agreements and fast -track authority. *American Journal of Public Health* 104(9), e7-e13.

733 Cuevas Garcia-Dorado, S., Cornselsen, C., Smith, R. & Walls, H. (2019). Economic globalization,
734 nutrition and health: a review of quantitative evidence. *Global Health* 15(1), 15.

735 Cutcliffe, J.R., Bajkay, R., Forester, S., Small, R., & Travale, R. (2011). Nurse migration in an
736 increasingly interconnected world: The case for internationalization of regulation of nurses and
737 nursing regulatory bodies. *Psychiatric Nursing*, 25(5), 320-328. doi: 10.1016/j.apnu.2011.03.006

738 Danby, M., Hart, R., Keneally, K., McAllister, J. & Templeman, S. (2018). Additional Comments –
739 Report 181. In, Joint Standing Committee on Treaties. *Inquiry into the Comprehensive and*
740 *Progressive Agreement for Trans-Pacific Partnership - Report 181*. Canberra: Commonwealth of
741 Australia. Retrieved from
742 [https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Treaties/TPP-](https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Treaties/TPP-11/Report_181)
743 [11/Report_181](https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Treaties/TPP-11/Report_181)

744 De Vogli, R. & Renzetti, N. (2016). The potential Impact of the Transatlantic Trade and Investment
745 Partnership (TTIP) on public health. *Epidemiologia & Prevenzione* 40(2), 95-102.

746 Delany, L., Signal, L. & Thomson, G. (2018). International trade and investment law: a new
747 framework for public health and the common good. *BMC Public Health* 18(1), 602.

748 Drope, J., & Lencucha, R. (2013). Tobacco Control and Trade Policy: Proactive Strategies for
749 Integrating Policy Norms. *Journal of Public Health Policy*, 34(1), 153-64.
750 doi: 10.1057/jphp.2012.36.

751 Drope, J. & Lencucha, R. (2014). Evolving Norms at the Intersection of Health and Trade. *Journal of*
752 *Health, Politics, Policy and Law*, 39(3), 591-631.
753 doi.org/10.1215/03616878-2682621

754 Eagar, K., Westera, A., Snoek, M., Kobel, C., Loggie, C. & Gordon, R. (2019). How Australian
755 residential aged care staffing levels compare with international and national benchmarks.
756 Centre for Health Service Development, Australian Health Services Research Institute,

757 University of Wollongong. Retrieved from
 758 <https://agedcare.royalcommission.gov.au/publications/Documents/research-paper-1.pdf>

759 Fidler, D.P., Drager, N., Correa, C., & Aginam O. (2006). Making commitments in health services
 760 under the GATS: Legal dimensions (pp. 141-167). In, C. Blouin, N. Drager & R. Smith (Eds.),
 761 *International trade in health services and the GATS: Current issues and debates*. Washington DC:
 762 The International Bank for Reconstruction and Development/The World Bank. Retrieved from
 763 [http://www.nsi-ins.ca/wp-content/uploads/2012/10/2006-International-Trade-in-Health-](http://www.nsi-ins.ca/wp-content/uploads/2012/10/2006-International-Trade-in-Health-Services-and-the-GATS-Current-Issues-and-Debates.pdf)
 764 [Services-and-the-GATS-Current-Issues-and-Debates.pdf](http://www.nsi-ins.ca/wp-content/uploads/2012/10/2006-International-Trade-in-Health-Services-and-the-GATS-Current-Issues-and-Debates.pdf)

765 Fooks, G. & Gilmore, A. B. (2014). International trade law, plain packaging and tobacco industry
 766 political activity: the Trans-Pacific Partnership. *Tobacco Control* 23(1), e1.

767 Friel, S., Gleeson, D., Thow, A.M., Labonté, R., Stuckler, D., Kay, D. & Snowdon, W. (2013). A New
 768 Generation of Trade Policy: Potential Risks to Diet-Related Health from the Trans Pacific
 769 Partnership Agreement. *Global Health*. 9, 46. doi: 10.1186/1744-8603-9-46.

770 Ford, M. & Kumiko, K. (2016). Regulatory approaches to managing skilled migration: Indonesian
 771 nurses in Japan. *The Economic and Labour Relations Review*, 27(2), 231-247.
 772 doi:org/10.1177/1035304616629580

773 Fujita, N., Matsuoka, S., Koto-Shimada, K., Ikarashi, M., Hazarika, I. & Zwi, A. B. (2019). Regulation of
 774 nursing professionals in Cambodia and Vietnam: a review of the evolution and key influences.
 775 *Human Resources for Health*, 17(1), 48.

776 Gleeson, D. H., Tienhaara, K. S., & Faunce, T. A. (2012). Challenges to Australia's national health
 777 policy from trade and investment agreements. *Medical Journal of Australia*, 196(5), 1-3.
 778 doi: 10.5694/mja11.11635

779 Gleeson, D. Lopert, R. & Reid, P. (2013). How the Trans Pacific Partnership Agreement could
 780 undermine PHARMAC and threaten access to affordable medicine and health equity in New
 781 Zealand. *Health Policy* 112(3):227-33 doi.org/10.1016/j.healthpol.2013.07.021

782 Gleeson, D., & Friel, S. (2013). Emerging threats to public health from regional trade agreements.
783 *The Lancet*, 381(9876), 1507-1509. doi: 10.1016/S0140-6736(13)60312-8

784 Gleeson, D. H., Moir, H., & Lopert, R. (2015). Costs to Australian taxpayers of pharmaceutical
785 monopolies and proposals to extend them in the trans-pacific partnership agreement. *Medical*
786 *Journal of Australia*, 202(6), 306-309. doi: 10.5694/mja14.01682

787 Gleeson, D., Lexchin, J., Lopert, R., & Kilic, B. (2018). The trans-pacific partnership agreement,
788 intellectual property and medicines: Differential outcomes for developed and developing
789 countries. *Global Social Policy*, 18(1), 7-27. doi: 10.1177/1468018117734153

790 Gleeson, D., Lexchin, J., Labonté, R., Townsend, B., Marc-André Gagnon, M-A., Kohler, J.,
791 Forman, L & Shadlen, K.C. (2019) Analyzing the impact of trade and investment agreements on
792 pharmaceutical policy: provisions, pathways and potential impacts. *Global Health 2019*, 15(Suppl
793 1):78 doi: 10.1186/s12992-019-0518-2

794 Government of the Commonwealth of Australia, Department of Foreign Affairs and Trade (2018a).
795 *Comprehensive and progressive agreement for trans-pacific partnership (CPTPP) suspensions*
796 *explained*. Canberra: Commonwealth of Australia. Retrieved from
797 [https://dfat.gov.au/trade/agreements/in-force/cptpp/outcomes-documents/Pages/cptpp-](https://dfat.gov.au/trade/agreements/in-force/cptpp/outcomes-documents/Pages/cptpp-suspensions-explained.aspx)
798 [suspensions-explained.aspx](https://dfat.gov.au/trade/agreements/in-force/cptpp/outcomes-documents/Pages/cptpp-suspensions-explained.aspx)

799 Government of the Commonwealth of Australia, Department of Foreign Affairs and Trade (2018b).
800 *National interest analysis: Comprehensive and progressive agreement for trans-pacific*
801 *partnership between the Government of Australia and the Governments of Brunei Darussalam,*
802 *Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam, and*
803 *associated side letters*. Canberra: Commonwealth of Australia. Retrieved from
804 [https://dfat.gov.au/trade/agreements/in-force/cptpp/Pages/comprehensive-and-progressive-](https://dfat.gov.au/trade/agreements/in-force/cptpp/Pages/comprehensive-and-progressive-agreement-for-trans-pacific-partnership.aspx)
805 [agreement-for-trans-pacific-partnership.aspx](https://dfat.gov.au/trade/agreements/in-force/cptpp/Pages/comprehensive-and-progressive-agreement-for-trans-pacific-partnership.aspx)

806 Hawkins, B. & Holden, C. (2016). A Corporate Veto on Health Policy? Global Constitutionalism and
807 Investor-State Dispute Settlement. *Journal of Health Politics, Policy and Law*, 41(5), 969-995.
808 doi: 10.1215/03616878-3632203

809 Health Workforce Australia (2014). *Australia's future health workforce – nurses detailed*. Canberra:
810 Commonwealth of Australia. Retrieved from
811 [http://www.health.gov.au/internet/main/publishing.nsf/Content/australias-future-health-](http://www.health.gov.au/internet/main/publishing.nsf/Content/australias-future-health-workforce-nurses)
812 [workforce-nurses](http://www.health.gov.au/internet/main/publishing.nsf/Content/australias-future-health-workforce-nurses)

813 Hoekman, B., & OeZden, C. (2010). The Euro-mediterranean partnership: Trade in services as an
814 alternative to migration *Journal of Common Market Studies*, 48(4), 835-857. doi:
815 10.1111/j.1468-5965.2010.02076.x

816 † Hoen, E. (2016). Private Patents and Public Health: Changing Intellectual Property Rules for Access
817 to Medicines. Amsterdam, The Netherlands: Health Action International.

818 International Council of Nurses (2002). *Definition of nursing*. Geneva: International Council of
819 Nurses. Retrieved from <https://www.icn.ch/nursing-policy/nursing-definitions>

820 International Labour Organization. (1998). *ILO declaration on fundamental principles and rights at*
821 *work and its follow-up*. Geneva: International Labour Organization. Retrieved from
822 <https://www.ilo.org/declaration/thedeclaration/textdeclaration/lang--en/index.htm>

823 International Labour Organization. (2002). The International Labour Organization's Fundamental
824 Conventions, Geneva: The International Labour Office. Retrieved from
825 [https://www.ilo.org/wcmsp5/groups/public/---ed_norm/---](https://www.ilo.org/wcmsp5/groups/public/---ed_norm/---declaration/documents/publication/wcms_095895.pdf)
826 [declaration/documents/publication/wcms_095895.pdf](https://www.ilo.org/wcmsp5/groups/public/---ed_norm/---declaration/documents/publication/wcms_095895.pdf)

827 Jarman, H., & Greer, S. (2010). Crossborder trade in health services: Lessons from the European
828 laboratory. *Health Policy*, 94(2), 158-163. doi: 10.1016/j.healthpol.2009.09.007

829 Jarman, H. (2017). Trade Policy Governance: What Health Policymakers and Advocates Need to
830 Know. *Health Policy*.121(11),1105-1112. doi: 10.1016/j.healthpol.2017.09.002.

831 Johnston, M. (2019). A brief history of international trade agreements. New York: Newstex.
 832 Retrieved from [https://search-proquest-](https://search-proquest-com.ezproxy.lib.monash.edu.au/docview/2295434638?accountid=12528)
 833 [com.ezproxy.lib.monash.edu.au/docview/2295434638?accountid=12528](https://search-proquest-com.ezproxy.lib.monash.edu.au/docview/2295434638?accountid=12528)

834 Jurje, F., & Lavenex, S. (2018). Mobility norms in free trade agreements: Migration governance in
 835 Asia between regional integration and free trade. *European Journal of East Asian Studies*, 17(1),
 836 83-117. doi: 10.1163/15700615-01701005

837 Kelaher, D., Dollery, B., & Grant, B. (2011). Trade liberalization in Indonesian health services:
 838 prospects and policies. *International Journal of Public Administration*, 34(8), 528-538. doi:
 839 10.1080/01900692.2011.583764

840 Kickbusch, I. & Szabo, M.M.(2014). A new governance space for health. *Global Health Action* 7,
 841 23507.

842 Kurniati, A., Chen, C. M., Efendi, F., & Ogawa, R. (2017). A deskilling and challenging journey: The
 843 lived experience of Indonesian nurse returnees. *International Nursing Review*, 64(4), 494-501.
 844 doi: 10.1111/inr.12352

845 Labonté, R., Sanders, D., Mathole, T., Crush, J., Chikanda, A., Dambisya, Y., & Bourgeault, I.L. (2015).
 846 Health worker migration from South Africa: Causes, consequences and policy responses. *Human*
 847 *Resources for Health*, 13(1). doi: 10.1186/s12960-015-0093-4

848 Labonté, R., Schram, A., & Ruckert, A. (2016). The trans-pacific partnership agreement and health:
 849 Few gains, some losses, many risks. *Globalization and Health*, 12(25), 1-7. doi: 10.1186/s12992-
 850 016-0166-8

851 Labonté, R., Schram, A., & Ruckert, A. (2016). The trans-pacific partnership: Is it everything we
 852 feared for health? *International Journal of Health Policy and Management*, 5(8), 487-496. doi:
 853 10.15171/ijhpm.2016.41

854 Labonté, R., Schram, A., & Ruckert A. (2017). The TPP is dead, long live the TPP? A response to recent
 855 commentaries. *International Journal of Health Policy and Management*, 6(4), 1-3. doi:
 856 10.15171/ijhpm.2017.12

857 Labonté, R., Ruckert, A., & Schram, A. (2018). Trade, investment and the global economy: Are we
858 entering a new era for health? *Global Social Policy*, 18(1), 28-44. doi:
859 10.1177/1468018117731415

860 Labonté, R., Crosbie, E., Gleeson, D., McNamara, C. (2019). USMCA (NAFTA 2.0): tightening the
861 constraints on the right to regulate for public health. *Global Health*, 15(1):44. doi:
862 10.1186/s12992-019-0476-8

863 Labonté, R. (2019). Trade , investment and public health: compiling the evidence, assembling the
864 arguments. *Global Health* 15(1), 1. doi: 10.1186/s12992-018-0425-y.

865 Law, K.M., Te, V. & Hill, P.S. (2019). Cambodia's health professionals and the ASEAN Mutual
866 Recognition Arrangements: registration, education and mobility. *Human Resources for Health*,
867 17(1), 14. doi: 10.1186/s12960-019-0349-5

868 Lencucha, R. (2017). Is it time to say farewell to the ISDS system? Comment on "The trans-pacific
869 partnership: Is it everything we feared for health?" *International Journal of Health Policy and*
870 *Management*, 6(5), 289-291. doi: 10.15171/ijhpm.2016.125

871 Li, H., Nie, W., & Li, J. (2014). The benefits and caveats of international nurse migration. *International*
872 *Journal of Nursing Sciences*, 1(3), 314-317. doi: 10.1016/j.ijnss.2014.07.006

873 Light, D. W., & Lexchin, J. R. (2012). Pharmaceutical research and development: what do we get for
874 all that money? *British Medical Journal*. 345, 4348 doi.org/10.1136/bmj.e4348

875 Liua, J.X., Goryakin, Y., Maeda, A., Bruckner, T., & Scheffler, R. (2016). *Global health workforce labor*
876 *market projections for 2030. Policy research working paper; No. 7790*. Washington DC: World
877 Bank. Retrieved from <https://openknowledge.worldbank.org/handle/10986/25035>

878 McNeill, D., Birkbeck, C.D., Fukuda-Parr, S., Grover, A., Schrecker, T., & Stuckler, D. (2017). Political
879 origins of health inequities: Trade and investment agreements. *The Lancet*, 389(10070), 760-
880 762. doi: 10.1016/S0140-6736(16)31013-3

881 McNamara, C., & Labonté, R. (2017). Trade, Labour Markets and Health: A Prospective Policy
882 Analysis of the Trans-Pacific Partnership. *International Journal of Health Services*, 47(2), 277–
883 297. <https://doi.org/10.1177/0020731416684325>

884 Mackey, T.K., Liang, B. A. & Novotny, T.E. (2013). Evolution of tobacco labeling and packaging:
885 international legal considerations and health governance. *American Journal of Public Health*,
886 103(4), e39-43.

887 Manaf, N. A., Koshy, K. C., & Ibrahim, K. (2014). The trans-pacific partnership agreement (TPPA):
888 Impact on health in Malaysia. *International Journal of Innovation and Applied Studies*, 7(3),
889 1156-1169. Retrieved from [http://www.ijias.issr-journals.org/abstract.php?article=IJIAS-14-190-](http://www.ijias.issr-journals.org/abstract.php?article=IJIAS-14-190-02)
890 02

891 Manning, C., & Sidorenko, A. (2007). The regulation of professional migration: Insights from the
892 health and IT sectors in ASEAN. *The World Economy*, 30(7), 1084-1113. doi: 10.1111/j.1467-
893 9701.2007.01013.x

894 Mashayekhi, M., Julsaint, M. & Tuerk, E. (2006). Strategic considerations for developing countries:
895 The case of GATS and health services (pp. 17-81). In, C. Blouin, N. Drager & R. Smith (Eds.),
896 *International trade in health services and the GATS: Current issues and debates*. Washington,
897 DC: The International Bank for Reconstruction and Development/The World Bank. Retrieved
898 from [http://www.nsi-ins.ca/wp-content/uploads/2012/10/2006-International-Trade-in-Health-](http://www.nsi-ins.ca/wp-content/uploads/2012/10/2006-International-Trade-in-Health-Services-and-the-GATS-Current-Issues-and-Debates.pdf)
899 [Services-and-the-GATS-Current-Issues-and-Debates.pdf](http://www.nsi-ins.ca/wp-content/uploads/2012/10/2006-International-Trade-in-Health-Services-and-the-GATS-Current-Issues-and-Debates.pdf)

900 Meyer, T.& Sitaraman, G. (2019). Trade and the separation of powers. *California Law Review*, 107(2),
901 583-672. Retrieved from
902 [https://scholarship.law.vanderbilt.edu/cgi/viewcontent.cgi?article=2103&context=faculty-](https://scholarship.law.vanderbilt.edu/cgi/viewcontent.cgi?article=2103&context=faculty-publications)
903 [publications](https://scholarship.law.vanderbilt.edu/cgi/viewcontent.cgi?article=2103&context=faculty-publications)

904 Mercurio, B. (2014). International investment agreements and public health: neutralizing a threat
905 through treaty drafting. *Bulletin of the World Health Organization*. 92(7), 520-525.

906 Milstien, J. & Kaddar, m. (2006). Managing the effect of TRIPS on availability of priority vaccines.
 907 *Bulletin of the World health Organization* 84(5), 360-365.

908 Ostry, J.D., Loungani, P., & Furceri, D. (2016). Neoliberalism: Oversold? *Finance & Development*.
 909 53 :(2), 38-41. Retrieved from <https://www.imf.org/external/pubs/ft/fandd/2016/06/ostry.htm>

910 Panizzon, Marion. (2011). Migration and Trade: Prospects for Bilateralism in the Face of Skill-
 911 Selective Mobility Laws. *Melbourne Journal of International Law*, 11(2). Retrieved from
 912 <https://ssrn.com/abstract=1596816>

913 Parliament of the Commonwealth of Australia, Foreign Affairs Defence and Trade References
 914 Committee (2018). Proposed comprehensive and progressive agreement for trans-pacific
 915 partnership. Canberra: Commonwealth of Australia. Retrieved from
 916 [https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Foreign_Affairs_Defence](https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Foreign_Affairs_Defence_and_Trade/TPP-11/Report)
 917 [_and_Trade/TPP-11/Report](https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Foreign_Affairs_Defence_and_Trade/TPP-11/Report)

918 Parliament of the Commonwealth of Australia, Joint Standing Committee on Treaties (2016). Report
 919 165: Trans-pacific partnership agreement. Canberra: Commonwealth of Australia. Retrieved
 920 from
 921 [https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Treaties/TransPacificPartn](https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Treaties/TransPacificPartnership/Report_165)
 922 [ership/Report_165](https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Treaties/TransPacificPartnership/Report_165)

923 Parliament of the Commonwealth of Australia, Joint Standing Committee on Treaties (2018). Inquiry
 924 into the Comprehensive and Progressive Agreement for Trans-Pacific Partnership – Report 181.
 925 Canberra: Commonwealth of Australia. Retrieved from
 926 [https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Treaties/TPP-](https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Treaties/TPP-11/Report_181)
 927 [11/Report_181](https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Treaties/TPP-11/Report_181)

928 Puig, S. & Strezhnev, A. (2017). The David Effect and ISDS. *European Journal of International Law*,
 929 28(3), 731–761, doi.org/10.1093/ejil/chx058.

930 Pusceddu, P. (2018). Assessing Access to Medicines in Preferential Trade Agreements: From the
 931 Trans-Pacific Partnership to the Comprehensive and Progressive Agreement for Trans-Pacific

932 Partnership. *IIC - International Review of Intellectual Property and Competition Law*, 49(9),
 933 1048-1079, doi.org/10.1007/s40319-018-0758-3.

934 Ramasamy, S., Krishnan, V., Bedford, R., & Bedford, C. (2008). The recognised seasonal employer
 935 policy: Seeking the elusive triple wins for development through international migration. *Pacific*
 936 *Economic Bulletin*, 23(3), 171-186.

937 Rietig, V., & Squires, A. (2015). *Building skills in North and Central America: Barriers and policy*
 938 *options toward harmonizing qualifications in nursing*. Washington, DC: Migration Policy
 939 Institute. Retrieved from [http://www.migrationpolicy.org/research/building-skills-north-and-](http://www.migrationpolicy.org/research/building-skills-north-and-central-america-barriers-and-policy-options-toward-harmonizing)
 940 [central-america-barriers-and-policy-options-toward-harmonizing](http://www.migrationpolicy.org/research/building-skills-north-and-central-america-barriers-and-policy-options-toward-harmonizing)

941 Rimmer, M. (2017). The trans-pacific partnership: Intellectual property, public health, and access to
 942 essential medicines. *Intellectual Property Journal*, 29(2), 277-332.

943 Ruckert, A.P., Schram, A.M., & Labonté, R.P. (2015). The trans-pacific partnership agreement:
 944 Trading away our health? *Canadian Journal of Public Health*, 106(4), E249-E251. doi:
 945 10.1080/09581596.2016.1178379

946 Schram, A.P., & Labonté, R.P. (2017). Trade and public health. *Canadian Medical Association Journal*,
 947 189(26), E879-E880. doi: 10.1503/cmaj.170089

948 Schram, A., Ruckert, A., Van Duzer, J.A., Friel, S., Gleeson, D., Thow, A.M., Stuckler, D. & Labonté, R.
 949 (2018). A conceptual framework for investigating the impacts of international trade and
 950 investment agreements on non communicable disease risk factors. *Health Policy Planning*
 951 33(10). 123-136.

952 Schram, A., Townsend, B., Youde, J., & Friel, S. (2019). Public health over private wealth: rebalancing
 953 public and private interests in international trade and investment agreements. *Public Health*
 954 *Research & Practice*. 29(3). doi: 10.17061/phrp2931919.

955 Sheargold, E. & Mitchell, A. (2016). The TPP and good regulatory practices: An opportunity for
 956 regulatory coherence to promote regulatory autonomy. *World Trade Review*, 15(4), 587-612.
 957 doi: 10.1017/S1474745616000045

958 Shingal, A., Martin, R. & Sauvé, P. (2018), WTO+ Commitments on Services in Asian PTAs: The Role of
 959 Regulatory Homogeneity and Goods Trade Complementarity. ARTNeT Working Paper Series,
 960 No. 178, February 2018, Bangkok, ESCAP. Retrieved from
 961 [https://artnet.unescap.org/publications/working-papers/wto-commitments-services-asian-
 963 ptas-role-regulatory-homogeneity-and](https://artnet.unescap.org/publications/working-papers/wto-commitments-services-asian-

 962 ptas-role-regulatory-homogeneity-and)
 964 Smith, R., Blouin, C. & Drager, N. (2015). Trade and health – the linkages in Smith, R., Blouin, C.,
 965 Mirza, Z., Beyer, P. & Drager, N. (Eds). *Trade and Health: Towards building a National Strategy.*
 966 *Switzerland: WHO Press. World Health Organisation.* Retrieved from
 967 [https://apps.who.int/iris/bitstream/handle/10665/183934/9789241565035_?jsessionid=A82C0
 968 C90D8FD5E4B3EFD1F32764947F7?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/183934/9789241565035_?jsessionid=A82C0C90D8FD5E4B3EFD1F32764947F7?sequence=1)
 969 Smith, R.D., Chanda, R., & Tangcharoensathien, V. (2009). Trade and health 4: Trade in health-
 970 related services. *The Lancet*, 373(9663), 593-601. doi: 10.1016/S01406736(08)61778-X
 971 Son, K.B., Lopert, R., Gleeson, D. & Lee, T. S. (2018) Moderating the impact of patent linkage on
 972 access to medicines: lessons from variations in South Korea, Australia, Canada, and the United
 973 States. *Global Health* 14(1). 101.
 974 Tham, J.C., & Ewing, K. (2016). Labour clauses in the TPP and TTIP: A comparison without a
 975 difference? *Melbourne Journal of International Law*, 17(2), 369-403.
 976 Thow, A.M., Snowdon, W., Labonté, R., Gleeson, D., Stuckler, D., Hattersley, L., & Friel, S. (2015). Will
 977 the next generation of preferential trade and investment agreements undermine prevention of
 978 noncommunicable diseases? A prospective policy analysis of the trans-pacific partnership
 979 agreement. *Health Policy*, 119(1), 88-96. doi: 10.1016/j.healthpol.2014.08.002
 980 Thow, A.M. & Gleeson, D. (2017). Advancing Public Health on the Changing Global Trade and
 981 Investment Agenda Comment on “ The Trans-Pacific Partnership: Is it Everything We Feared for
 Health. *International Journal of Health Policy Management* 6(5). 295-298.

982 Thow, A.M., Jones, A., Hawkes, C., Ali, I. & Labonté, R. (2017). Nutrition Labelling Is a Trade Policy
 983 Issue: Lessons from an Analysis of Specific Trade Concerns at the World Trade Organization.
 984 *Health Promotion International*, 33(4). 561-571. doi: 10.1093/heapro/daw109.

985 Tienhaara K. (2011). Regulatory Chill and the Threat of Arbitration: A View from Political Science. In:
 986 Brown C, Miles K, (Eds). *Evolution in Investment Treaty Law and Arbitration*. Cambridge:
 987 Cambridge University Press; p. 606-628.

988 Trans-Pacific Partnership Agreement (2018). 25. *Regulatory Coherence*. Canberra: Commonwealth of
 989 Australia. Retrieved from [https://dfat.gov.au/trade/agreements/in-force/cptpp/official-](https://dfat.gov.au/trade/agreements/in-force/cptpp/official-documents/Documents/25-regulatory-coherence.pdf)
 990 [documents/Documents/25-regulatory-coherence.pdf](https://dfat.gov.au/trade/agreements/in-force/cptpp/official-documents/Documents/25-regulatory-coherence.pdf)

991 Trans-Pacific Partnership Agreement (2018). *Annexe 26-A. Transperancy and Procedural Fairness for*
 992 *Pharmaceutical Products and Medical Devices*. Canberra: Commonwealth of Australia Retrieved
 993 from <https://www.dfat.gov.au/sites/default/files/26-transparency-and-anti-corruption.pdf>

994 Tricco, AC, Lillie, E, Zarin, W, O'Brien, KK, Colquhoun, H, Levac, D... Straus, S.E. (2018). PRISMA
 995 extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Annals of Internal*
 996 *Medicine*, 169(7):467-473. doi:10.7326/M18-0850.

997 Voon, T. (2017). Balancing regulatory autonomy with liberalisation of trade in services: An analytical
 998 assessment of Australia's obligations under preferential trade agreements. *Melbourne Journal*
 999 *of International Law*, 18(2), 373-406.

1000 Walls, H.L., Smith, R.D. & Drahos, P. (2015). Improving regulatory capacity to manage risks
 1001 associated with trade agreements. *Global Health* 11.14

1002 Weishaar, H., Collin, j., Smith, K., Gruning, T., Mandal, S. & Gilmore, A. (2012). Global health
 1003 governance and the commercial sector: a documentary analysis of tobacco company strategies
 1004 to influence the WHO framework convention on tobacco control. *PLoS Medicine* 9(6).
 1005 E1001249.

1006 World Trade Organization (1995) Agreement on Trade -Related Aspects of Intellectual Property
1007 Rights. Retrieved from https://www.wto.org/english/docs_e/legal_e/27-trips_01_e.htm
1008 Yeates, N. & Pillinger, J. (2018). International healthcare worker migration in Asia Pacific:
1009 International policy responses. *Asia Pacific Viewpoint*. 59(1), 92-106. Retrieved from
1010 onlinelibrary.wiley.com/doi/epdf/10.1111/apv.12180
1011